Table 1.
Baseline clinical‐pathological characteristics among 112 women with EOC
| Clinical features | Mean (SD) or n (%) |
|---|---|
| Age, years | 58.1 ± 12.6 |
| BMI, kg/m2 | 26.7 ± 4.9 |
| Ethnicity | |
| Non‐white | 8 (7.1) |
| White | 104 (92.9) |
| Menopause | |
| No | 23 (20.5) |
| Yes | 89 (79.5) |
| Histological subtypesa | |
| LGS and other | 38 (33.9) |
| HGS and other | 74 (66.1) |
| CA 125 (U/mL) | 1433.8 ± 2720.8 |
| FIGO stage | |
| I + II | 34 (30.4) |
| III + IV | 78 (69.6) |
| Postsurgery residual disease | |
| No | 43 (38.4) |
| Yes | 69 (61.6) |
| Type of treatment | |
| Neoadjuvant | 51 (45.5) |
| Adjuvant | 61 (54.5) |
| Chemotherapy treatment | |
| Carboplatin | 1 (0.9) |
| Carboplatin/paclitaxel | 111 (99.1) |
BMI, body mass index; EOC, epithelial ovarian cancer; FIGO, The International Federation of Gynecology and Obstetrics; HGS, high grade serous; LGS, low grade serous.
a
Histological subtypes: HGS and other: 66 (89.2%) cases of HGS carcinomas, 6 (8.1%) undifferentiated, 2 (3.1%) carcinosarcomas; LGS and other: 9 (23.7%) cases of endometrioid low grade carcinomas, 9 (23.7%) cases of clear cell carcinomas, 8 (21.1%) cases of mucinous, 6 (15.8%) cases of LGS carcinomas, and 6 (15.8%) cases of mixed carcinomas.